Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: KRP-209; MRZ 2/579

Latest Information Update: 15 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merz Pharma
  • Developer Forest Laboratories; Kyorin Pharmaceutical; Merz Pharma
  • Class Antidementias; Cyclopentanes; Drug withdrawal therapies; Small molecules
  • Mechanism of Action Nicotinic receptor antagonists; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Tinnitus
  • Discontinued Alcoholism; Alzheimer's disease; Pain; Pathologic nystagmus

Most Recent Events

  • 06 Nov 2017 Kyorin Pharmaceutical completes a phase II trial for Tinnitus in Japan (PO) (JapicCTI-152984)
  • 16 Mar 2012 Merz terminates phase III trial (long-term study) in Tinnitus in USA, Europe, and Mexico (NCT00827008)
  • 31 Aug 2011 Phase-II clinical trials in Tinnitus in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top